Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869959 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2405319 in Participants With Type 2 Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT01869959 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 47 participants.
The verdict
NCT01869959, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It was given as a daily injection under the skin to participants with type 2 diabetes mellitus (T2DM) for 28 days. This study determined how long the drug stays in the body and how it affects blood sugar levels. After screening, the study lasted about 2 months for each participant. Participants continued their prestudy regimen of diet and exercise alone or in combination with metformin.
Interventions
- DRUG Placebo
- DRUG LY2405319
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01869959
The ClinicalTrials.gov registry entry for NCT01869959 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01869959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01869959 about?
NCT01869959 is a clinical study titled "A Study of LY2405319 in Participants With Type 2 Diabetes". The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It was given as a daily injection under the skin to participants with type 2 diabetes mellitus (T2DM) for 28 days. This study determined how long the drug stays in the body and how it affects blood sugar levels....
What is the current status of trial NCT01869959?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2009-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT01869959?
The interventions under investigation include: Placebo (DRUG), LY2405319 (DRUG).
Who is sponsoring clinical trial NCT01869959?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.